News archive

28 Jan 2011Actelion and GSK Discontinue Clinical Development of Almorexant
10 Jan 2011Actelion to Present at the 29th Annual J.P. Morgan Healthcare Conference
03 Jan 2011Actelion announces change in its Board of Directors
10 Dec 2010 Actelion Opens New Business Center
17 Nov 2010Actelion Statement
21 Oct 2010Actelion announces third quarter 2010 financial results
21 Oct 2010Actelion announces CHF 800 million share repurchase program
27 Sep 2010CONSCIOUS-2 study with clazosentan does not meet primary endpoint
20 Sep 2010Actelion Pharmaceuticals US, Inc. has received subpoena relating to Tracleer
20 Jul 2010Actelion obtains option to acquire privately-held Trophos
20 Jul 2010Actelion announces second quarter 2010 financial results
17 May 2010Actelion announces presentation of positive Phase II results with selexipag in patients with pulmonary arterial hypertension at the American Thoracic Society 2010 International Conference
04 May 2010Actelion's Annual General Meeting of Shareholders held in Basel, Switzerland
22 Apr 2010Actelion announces first quarter 2010 financial results
09 Mar 2010Actelion receives FDA complete response letter for Zavesca (miglustat) for the treatment of Niemann-Pick type C disease
01 Mar 2010BUILD-3 study with bosentan in idiopathic pulmonary fibrosis does not meet primary endpoint
18 Feb 2010Actelion publishes Annual Report 2009
18 Feb 2010Actelion announces Full year 2009 financial results
05 Feb 2010Actelion to Present at the 12th Annual BIO CEO & Investor Conference
12 Jan 2010Zavesca® (miglustat) receives positive vote from the FDA's Endocrinologic and Metabolic Drugs Advisory Committee for the treatment of Niemann-Pick type C disease
Page:  1 2 3 4 5 6 7 8 9 10 11 12 13 14

Contact

Media Relations
Actelion Pharmaceuticals Ltd
Gewerbestrasse 16
CH-4123 Allschwil
Switzerland
Phone:+41 61 565 62 62
Fax:+41 61 565 65 07
Contact us onlineHow to get to us

Top of pageSendbookmarkPrint page